COVID-19 preclinical drug development database

Pneumagen - biologics for prevention and treatment of COVID-19

Pneumagen Ltd

Added 15/05/2020 | Updated 15/05/2020

Project Details

Type of project

  • Tier 2: testing existing molecules

Therapeutic target

  • Preventing infection (prophylaxis or preventing cell entry)

Type of supporting technology

Phase of project

  • PK/PD testing and toxicology

Modality (if can be disclosed)*

  • Biologic: multivalent carbohydrate binding modules

Molecular/cellular target (if known or can be disclosed)*

  • SARS-CoV-2 Spike protein
  • Glycan targeting of both virus and cell surface

Partner institutions/organisations

  • University of St Andrews

Key contact

Name: Douglas Thomson (CEO)

Email Address: douglas.thomson@pneumagen.com

Phone Number:

Key Collaborators:

Anticipated timeframe of future outputs

3-6 months

This research project is looking for the following:

animal models for COVID-19, further in vitro testing for COVID-19, MERS

Further Details

Abstract or additional information (if available)*

Pneumagen has developed Neumifil, a mutlivalent sialic acid binding biologic, which we have shown protects mice from lethal doses of all influenza viruses tested (e.g. pandemic 2009 H1N1, avian H5N1, Shanghai H7N9). We have also shown antiviral activity against RSV in an animal model. PHE and Glasgow's CVR tested Neumifil, and other of our biologics, in vitro against SARS-CoV-2. Very significant antiviral activity was shown in both a preventative and a treatment assay. We are progressing towards first-in-human trials early next year.

Published outputs (if available)*

10.1073/pnas.1404205111, 10.1128/AAC.04431-14